Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• Among participants aged >= 12 years with type 1 or type 2 hereditary angioedema, median time to symptom relief was 1.61 hours (interquartile range [IQR], 0.78-7.04) with the 300-mg dose and 1.79 hours (IQR, 1.02-3.79) with the 600-mg dose of sebetralstat, compared to 6.72 hours (IQR, 1.34 to >12) with placebo (P < 0.001 for 300 mg; P = 0.001 for 600 mg).
• Median time to reduction in attack severity was 9.27 hours (IQR, 1.53 to >12) with the 300-mg dose and 7.75 hours (IQR, 2.19 to >12) with the 600-mg dose, versus >12 hours (IQR, 6.23 to >12) with placebo (P = 0.004 for 300 mg; P = 0.003 for 600 mg).
• Complete attack resolution within 24 hours occurred in 42.5 % of attacks with the 300-mg dose and 49.5 % with the 600-mg dose, compared to 27.4 % with placebo (P = 0.002 for 300 mg; P < 0.001 for 600 mg).
• Sebetralstat and placebo had similar safety profiles among participants aged >= 12 years with type 1 or type 2 hereditary angioedema.
• No serious adverse events related to the trial agents were reported.